

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KeyMed Biosciences**

**Keymed Biosciences Inc.**

**康諾亞生物醫藥科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2162)**

## **VOLUNTARY ANNOUNCEMENT**

### **STRATEGIC ALLIANCE AGREEMENT WITH SHANGHAI JMT-BIO TECHNOLOGY CO., LTD.**

Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on September 22, 2021, Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司, “**Chengdu Keymed**”), a wholly-owned subsidiary of the Company, has entered into a strategic alliance agreement (the “**Agreement**”) with Shanghai JMT-Bio Technology Co., Ltd. (上海津曼特生物科技有限公司, “**JMT-Bio**”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (“**CSPC**”).

Under the terms of the Agreement, Chengdu Keymed and JMT-Bio shall jointly identify, research, develop and commercialize one or more products for nervous system diseases (the “**Collaboration Products**”). Chengdu Keymed will primarily be responsible for pre-clinical research and development of the Collaboration Product(s) and JMT-Bio will primarily be responsible for clinical development and commercialization of the Collaboration Product(s).

Chengdu Keymed and JMT-Bio have agreed to establish a joint steering committee consisting of six members, with three members nominated by each of Chengdu Keymed and JMT-Bio, the joint steering committee shall discuss and determine, among other things, strategic and critical matters regarding the Collaboration Products.

The Company is also currently engaged in other collaboration arrangements with CSPC as set forth in the Company’s prospectus dated June 25, 2021. The Company believes that the strategic alliance will further strengthen the collaboration between the Company and CSPC, where the two parties will further utilize their respective advantages, coordinate their resources to jointly promote the development of nervous system diseases related drugs.

JMT-Bio is a wholly owned subsidiary of CSPC, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 1093. CSPC is a leading pharmaceutical group in China with a strong innovation, R&D and marketing capability. Its strong product portfolio includes products in the therapeutic areas of nervous system diseases, oncology, anti-infectives and cardiovascular diseases.

This announcement is made by the Company on a voluntary basis to provide information to shareholders and potential investors of the Company. There is no assurance that any Collaboration Products will ultimately be successfully developed, marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors  
**Keymed Biosciences Inc.**  
**Dr. Bo CHEN**  
*Chairman*

Hong Kong, September 23, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Dong LYU, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.*